Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone plus romiplostim versus dexamethasone alone in newly diagnosed primary immune thrombocytopenia
ISRCTN10454031Phase 3Active, not recruiting
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of romiplostim and dexamethasone in immune thrombocytopenia (ITP) (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: 6mSROT-50 at 6 months from treatment cessation. Started Dec 2022; status: active, not recruiting.
02
Drugs
romiplostimdexamethasone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ISRCTN10454031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10454031.